drugset / Trial / NCT01370369

Efficacy, Pharmacokinetics and Safety of Testosterone

NCT01370369

Phase 2 Completed 20 enrolled Ferring Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label study of a single and repeated application of three dose levels of topical testosterone in hypogonadal males with morning serum testosterone concentrations \< 297 ng/dL.

Timeline

Start
2011-05
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 1.25 ml Topical
Subject Testosterone Small molecule 2.5 ml Topical
Subject Testosterone Small molecule 3.75 ml Topical

Indications